Literature DB >> 6134884

Controlled trial of faecal occult blood testing in the detection of colorectal cancer.

J D Hardcastle, P A Farrands, T W Balfour, J Chamberlain, S S Amar, M G Sheldon.   

Abstract

20 525 patients from general practitioners' lists were randomly allocated into test and control groups. The 10 253 test subjects were invited to perform haemoccult faecal occult blood testing over 3 days. 3613 (36 . 8%) of the 9807 who received their invitations completed the test. Compliance was improved by direct invitation from the general practitioner and by prior health education by letter or interview. 77 people (2 . 1%) had a positive test result, and 50% of these on investigation had neoplastic disease--12 had invasive carcinomas (9 Dukes' stage A, 2 stage B, 1 stage C) and 27 had 40 adenomas (12 over 2 cm, 2 of which contained areas of severe dysplasia). In the year following the screening test 1 carcinoma (stage C) has presented in the group which accepted the test, and 10 carcinomas (4 stage B, 4 stage C, 2 stage D) have presented in the control group. This respresents a 3 . 6 times greater detection rate per 1000 persons in the test group than in the control group. Only 8 adenomas have presented in the control and non-responding groups. Fibreoptic sigmoidoscopy identified the 10 carcinomas within its range and 39 of the 40 adenomas. Double-contrast barium enema identified only 9 of the 12 carcinomas and 24 (62%) of the 40 adenomas. All 3 carcinomas not identified by barium enema were polypoid Dukes' stage-A lesions.

Entities:  

Mesh:

Year:  1983        PMID: 6134884     DOI: 10.1016/s0140-6736(83)90001-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  62 in total

1.  Occult blood testing for early detection of colorectal cancer: diagnostic outcomes.

Authors:  T G Hislop; B J Morrison; P E Hoogewerf; S D Burns; R Sizto
Journal:  Can Fam Physician       Date:  1987-12       Impact factor: 3.275

2.  Sexually transmitted viral infections in various population groups in Mogadishu, Somalia.

Authors:  H Jama; L Grillner; G Biberfeld; S Osman; A Isse; M Abdirahman; S Bygdeman
Journal:  Genitourin Med       Date:  1987-10

3.  Human cervical epithelial cells that express HLA-DR associated with viral infection and activated mononuclear cell infiltrate.

Authors:  S Fais; F Delle Fratte; F Mancini; V Cioni; M Guadagno; G Vetrano; F Pallone
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

4.  Early detection of colon cancer-the kaiser permanente northwest 30-year history: how do we measure success? Is it the test, the number of tests, the stage, or the percentage of screen-detected patients?

Authors:  David Moiel; John Thompson
Journal:  Perm J       Date:  2011

5.  Estimating development cost for a tailored interactive computer program to enhance colorectal cancer screening compliance.

Authors:  David R Lairson; Yu-Chia Chang; Judith L Bettencourt; Sally W Vernon; Anthony Greisinger
Journal:  J Am Med Inform Assoc       Date:  2006-06-23       Impact factor: 4.497

6.  Mass screening for colorectal cancer in Hungary.

Authors:  P Preisich; S Siba; E Szakátsy
Journal:  J R Soc Med       Date:  1987-06       Impact factor: 5.344

7.  Increased epithelial expression of HLA-DQ and HLA-DP molecules in salivary glands from patients with Sjögren's syndrome compared with obstructive sialadenitis.

Authors:  P S Thrane; T S Halstensen; H R Haanaes; P Brandtzaeg
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

8.  Perception errors with double-contrast enema after a positive guaiac test.

Authors:  J Kewenter; J Jensen; M Boijsen; G Lycke; U Tylén
Journal:  Gastrointest Radiol       Date:  1987

9.  Abnormal urothelial HLA-DR expression in interstitial cystitis.

Authors:  T J Christmas; G F Bottazzo
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

10.  Acceptability of opportunistic screening for occult gastrointestinal blood loss.

Authors:  F D Hobbs; R C Cherry; J W Fielding; L Pike; R Holder
Journal:  BMJ       Date:  1992-02-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.